Premium
Pharmacokinetic Profile of Topiramate in Comparison with Other New Antiepileptic Drugs
Author(s) -
Perucca Emilio
Publication year - 1996
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/j.1528-1157.1996.tb06032.x
Subject(s) - felbamate , lamotrigine , topiramate , pharmacokinetics , vigabatrin , medicine , anticonvulsant , antiepileptic drug , pharmacology , epilepsy , tiagabine , psychiatry
Summary: Antiepileptic drugs (AEDs) in broad use today have a number of pharmacokinetic liabilities, including a propensity for clinically meaningful drug interactions. Therefore, new AEDs with improved pharmacokinetic characteristics would be welcomed. The pharmacokinetic proftles of six newer AEDs—topiramate (TPM), gaba‐pentin (GBP), vigabatrin (VGB), lamotrigine (LTG), ox‐carbazepine (OCBZ), and felbamate—were reviewed. Some of these AEDs offer an improvement in one or more pharmacokinetic parameters compared with traditional AEDs, with TPM, GBP, VGB, and OCBZ demonstrating the most advantageous overall pharmacokinetic profiles.